Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ENROLLING_BY_INVITATION
NA
2400 participants
INTERVENTIONAL
2025-11-10
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
FACTORIAL
HEALTH_SERVICES_RESEARCH
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Source of recommendation - Physician
Participants read a hypothetical scenario where a doctor recommends stopping aspirin.
Additional harm information
Participants received additional information about the harm of continuing aspirin.
Less information
Participants will receive less information about the risk of harms of continuing aspirin.
Source of recommendation - Pharmacist
Participants read a hypothetical scenario where a pharmacist recommends stopping aspirin.
Additional harm information
Participants received additional information about the harm of continuing aspirin.
Less information
Participants will receive less information about the risk of harms of continuing aspirin.
Source of information - AI
Participants read a hypothetical scenario where artificial intelligence is used to recommend stopping aspirin.
Additional harm information
Participants received additional information about the harm of continuing aspirin.
Less information
Participants will receive less information about the risk of harms of continuing aspirin.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Additional harm information
Participants received additional information about the harm of continuing aspirin.
Less information
Participants will receive less information about the risk of harms of continuing aspirin.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 65 years and older
Exclusion Criteria
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Sydney
OTHER
University of Michigan
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sarah Vordenberg
Associate Chair and Clinical Professor Department of Clinical Pharmacy
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sarah Vordenberg, PharmD, MPH
Role: PRINCIPAL_INVESTIGATOR
University of Michigan
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Michigan
Ann Arbor, Michigan, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HUM00280646
Identifier Type: -
Identifier Source: org_study_id